Page 2 - Fred Schwarzer News Today

IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report)’s stock price traded down 6% during mid-day trading on Wednesday . The stock traded as low as $15.06 and last traded at $15.11. 40,803 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 310,863 shares. The stock had previously closed […]

IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report)’s stock price traded down 6% during mid-day trading on Wednesday . The stock traded as low as $15.06 and last traded at $15.11. 40,803 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 310,863 shares. The stock had previously closed […]

Shares of IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) have received an average recommendation of “Hold” from the nine research firms that are covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price […]

MOUNTAIN VIEW, Calif., Feb. 01, 2024 -- IGM Biosciences, Inc. , a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief...

IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) has earned an average recommendation of “Hold” from the nine analysts that are covering the company, MarketBeat reports. Six analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price objective among brokers that […]

IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) CEO Fred Schwarzer sold 17,576 shares of IGM Biosciences stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $5.78, for a total value of $101,589.28. Following the completion of the transaction, the chief executive officer now owns […]

By Denny Jacob IGM Biosciences will reduce its workforce by 22%, part of a broader overhaul within the company. The clinical-stage biotechnology company said...

– Third IND cleared for imvotamab in autoimmune diseases –

13.11.2023 - – Third IND cleared for imvotamab in autoimmune diseases – – International sites opened for aplitabart randomized clinical trial – MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) - IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage ...

- Randomized clinical trial of IGM-8444 plus FOLFIRI and bevacizumab in second line metastatic colorectal cancer underway - - Plans to present additional non-randomized clinical data for 3 mg/kg of IGM-8444